Discover 334 paid clinical trials in Mississippi. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Mississippi provides diverse clinical research opportunities, opening doors for healthy volunteers interested in paid studies, as well as people with specific health conditions to contribute to medical research. Research hubs in Jackson, Gulfport, and Hattiesburg are actively recruiting, granting participants access to innovative treatments and comprehensive care.
Filter
1
Filter results
Results: 334
Active & Responsive
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
for
Obesity or Overweight
Location: New York NY, Morehead City NC, Wilmington NC,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07575399
Phase 3, Recruiting
Active & Responsive
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
for
Coronavirus Disease (COVID-19)
Location: The Bronx NY, New York NY, Teaneck NJ, Newark NJ,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06667700
Phase 3, Recruiting
Active & Responsive
A Study of Brenipatide in Participants With Opioid Use Disorder
for
Opioid Use Disorder
Location: Boston MA, Watertown MA, Providence RI, The Bronx NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07420283
Phase 2, Recruiting
Active & Responsive
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
for
Age-Related Macular Degeneration
Location: Boston MA, Philadelphia PA, Atlanta GA, Ann Arbor MI,
Sponsor: Astellas Institute for Regenerative Medicine
Sex: All
Age: 50+
Code: NCT03178149
Phase 1, Recruiting
Active & Responsive
Caris Biorepository Research Protocol
for
Cancer, Early Detection of Cancer, Minimal Residual Disease
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care
for
Arthritis, Rheumatoid
Location: Smithtown NY, Danbury CT, Midland Park NJ, Summit NJ,
Sponsor: Crescendo Bioscience
Sex: All
Age: 18 - 70+
Code: NCT02832297
Recruiting
Active & Responsive
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
for
Irritable Bowel Syndrome
Location: Boston MA, Brooklyn NY, Laurel MD, Chevy Chase MD,
Sponsor: Dynogen Pharmaceuticals
Sex: Female
Age: 18 - 65
Code: NCT00547469
Phase 2, Phase 3, Recruiting
Active & Responsive
Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury
for
Spinal Cord Injuries, Spinal Cord Injury,
Location: Jackson MS
Sponsor: University of Mississippi Medical Center
Sex: All
Age: 18+
Code: NCT06274021
Early Phase 1, Recruiting
Active & Responsive
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: Halifax, Boston MA, New Haven CT, Queens NY,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 21
Code: NCT05183035
Phase 3, Recruiting
Active & Responsive
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
for
Sickle Cell Disease
Location: Grand Rapids MI, Indianapolis IN, Flowood MS
Sponsor: Agios Pharmaceuticals, Inc.
Sex: All
Age: 12+
Code: NCT07656415
Phase 3, Recruiting
Active & Responsive
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
for
ADHD
Location: Worcester MA, Springfield MA, Staten Island NY,
Sponsor: Axsome Therapeutics, Inc.
Sex: All
Age: 12 - 17
Code: NCT07717892
Phase 3, Recruiting
Active & Responsive
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
for
ADHD
Location: Worcester MA, Springfield MA, Staten Island NY,
Sponsor: Axsome Therapeutics, Inc.
Sex: All
Age: 6 - 11
Code: NCT07717879
Phase 3, Recruiting
Active & Responsive
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Locally Advanced Non-Small Cell Lung Cancer (NSCLC),